Skip to main content
Home > The Daily Extra > Company News

Chronological Index of BioCentury Extra, The Daily News: Company News

BioCentury Extra, The Daily News Current Issue
  • COMPANY NEWS: FDA lifts hold on Idenix's IDX184

    Idenix Pharmaceuticals Inc. (NASDAQ:IDIX) said FDA lifted a partial clinical hold on HCV product IDX184 after reviewing interim data from 31 patients in a Phase IIb trial. The biotech now plans to enroll an additional …

    Published on 2/3/2012
  • COMPANY NEWS: NICE recommends against breast cancer diagnostics

    The U.K.'s NICE issued draft guidance recommending against the use of three breast cancer diagnostics to guide decisions about chemotherapy use in women with estrogen receptor-positive, lymph node-negative, HER2-…

    Published on 2/3/2012
  • COMPANY NEWS: ODAC to review Talon's Marqibo

    FDA's Oncologic Drugs Advisory Committee will meet on March 21 to discuss an NDA from Talon Therapeutics Inc. (OTCBB:TLON) for Marqibo vincristine to treat Philadelphia chromosome-negative acute lymphoblastic leukemia (…

    Published on 2/3/2012
  • COMPANY NEWS: Threshold jumps on Merck KGaA cancer deal

    Threshold Pharmaceuticals Inc. (NASDAQ:THLD) gained $1.70 (132%) to $2.99 on Friday after partnering with Merck KGaA (Xetra:MRK) to co-develop and commercialize Threshold's cancer product TH-302. The product, a hypoxia-…

    Published on 2/3/2012
  • COMPANY NEWS: AstraZeneca restructuring

    AstraZeneca plc (LSE:AZN; NYSE:AZN) reported 4Q11 and FY11 financial results Thursday and announced a new restructuring initiative that includes 7,300 in employee cuts. About 2,200 R&D positions and 3,750 SG&A positions…

    Published on 2/2/2012
  • COMPANY NEWS: Dynavax up as FDA agrees to expanded Heplisav indication

    Dynavax Technologies Corp. (NASDAQ:DVAX) gained $0.40 (11%) to 4.06 on Thursday after agreeing with FDA to expand the age range of the proposed indication for the company's Heplisav HBV vaccine. Dynavax now plans to …

    Published on 2/2/2012
  • COMPANY NEWS: FDA to review Novo's insulin products, rebuffs rFXIII

    Novo Nordisk A/S (CSE:NVO; NYSE:NVO) said FDA accepted for review NDAs for a pair of its insulin products to treat Type I and II diabetes: insulin Degludec and DegludecPlus. The PDUFA date is July 29. Insulin Degludec …

    Published on 2/2/2012
  • COMPANY NEWS: Merck reports financial results, regulatory updates

    Merck & Co. Inc. (NYSE:MRK) reported financial results on Thursday and provided a regulatory update, including announcing FDA approval of an extended-release, once-daily formulation of Janumet sitagliptin/metformin to …

    Published on 2/2/2012
  • COMPANY NEWS: ODAC to discuss pazopanib, ridaforolimus

    FDA's Oncologic Drugs Advisory Committee will meet on March 20 to discuss applications for two sarcoma drugs -- Votrient pazopanib from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and Taltorvic ridaforolimus from Merck & Co…

    Published on 2/2/2012
  • COMPANY NEWS: ThromboGenics pulls ocriplasmin BLA; to resubmit in April

    ThromboGenics N.V. (Euronext:THR) withdrew a BLA for ocriplasmin to treat symptomatic vitreomacular adhesion (VMA) after receiving notice that FDA intended to grant the application a six-month Priority Review. …

    Published on 2/2/2012
  • COMPANY NEWS: FDA schedules panel for lorcaserin

    Arena Pharmaceuticals Inc. (NASDAQ:ARNA) received notice that FDA's Endocrinologic and Metabolic Drugs Advisory Committee will meet in 2Q12 to discuss the resubmitted NDA for lorcaserin to treat obesity. A specific …

    Published on 2/1/2012
  • COMPANY NEWS: IQWiG: Halaven offers 'no additional benefit' over chemo

    The German Institute for Quality and Efficiency in Health Care (IQWiG) said breast cancer drug Halaven eribulin mesylate from Eisai Co. Ltd. (Tokyo: 4523; Osaka:4523) provides "no additional benefit" over chemotherapy. …

    Published on 2/1/2012
  • COMPANY NEWS: IQWiG: Xiapex offers 'no additional benefit' over comparators

    The German institute for Quality and Efficiency in health Care (IQWiG) said Dupuytren's contracture drug Xiapex collagenase clostridium histolyticum from Pfizer Inc. (NYSE:PFE) demonstrated "no additional benefit" over …

    Published on 2/1/2012
  • COMPANY NEWS: NICE rebuffs Zytiga

    The U.K.'s NICE issued draft guidance recommending against Zytiga abiraterone from Johnson & Johnson (NYSE:JNJ) in combination with prednisone or prednisolone in patients with metastatic, castration-resistant prostate …

    Published on 2/1/2012
  • COMPANY NEWS: Sangamo jumps on ZFP deal with Shire

    Sangamo BioSciences Inc. (NASDAQ:SGMO) gained $0.74 (21%) to $4.19 on Wednesday after granting Shire plc (LSE:SHP; NASDAQ:SHPGY) exclusive, worldwide rights to zinc finger DNA-binding protein (ZFP) therapeutics …

    Published on 2/1/2012
  • COMPANY NEWS: UCB re-partners Cimzia in Japan with Astellas

    UCB Group (Euronext:UCB) partnered with Astellas Pharma Inc. (Tokyo:4503) to co-develop and co-commercialize UCB's anti-TNF therapy Cimzia certolizumab pegol in Japan. The new deal follows last month's announcement that…

    Published on 2/1/2012
  • COMPANY NEWS: FDA approves linagliptin/metformin

    Boehringer Ingelheim GmbH (Ingelheim, Germany) and partner Eli Lilly and Co. (NYSE:LLY) said FDA approved Jentadueto linagliptin/metformin to treat Type II diabetes. The partners plan to launch the product early this …

    Published on 1/31/2012
  • COMPANY NEWS: FDA to review Gattex

    FDA accepted for review an NDA from NPS Pharmaceuticals Inc. (NASDAQ:NPSP) for Gattex teduglutide to treat short bowel syndrome (SBS). NPS, which requested Priority Review, said it expects FDA to assign a PDUFA date …

    Published on 1/31/2012
  • COMPANY NEWS: Roche unveils slate for Illumina

    Roche (SIX:ROG; OTCQX:RHHBY) plans to nominate up to 11 directors for election to the board of Illumina Inc. (NASDAQ:ILMN) at the sequencing company's annual meeting this year as part of an unsolicited acquisition bid …

    Published on 1/31/2012
  • COMPANY NEWS: SkyePharma CEO Mueller resigns

    SkyePharma plc (LSE:SKP) said Axel Mueller resigned as CEO to pursue other interests. CFO Peter Grant replaces him. SkyePharma was up 2.38p to 34.38p on Tuesday.

    Published on 1/31/2012
  • COMPANY NEWS: Spectrum to co-develop Hanmi's long-acting G-CSF

    Hanmi Pharmaceutical Co. Ltd. (KOSDAQ:128940) and Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) partnered to co-develop Hanmi's neutropenia product SPI-2012 (formerly LAPS-GCSF). Spectrum has an option to license …

    Published on 1/31/2012
  • COMPANY NEWS: Transparency debuts open-source drug development plan

    Transparency Life Sciences LLC launched a prototype of its web platform through which patients, physicians, researchers and other stakeholders can provide input on clinical trial designs. The company believes that …

    Published on 1/31/2012
  • COMPANY NEWS: Cell Therapeutics withdraws Pixuvri NDA

    Cell Therapeutics Inc. (NASDAQ:CTIC; Milan:CTIC) withdrew an NDA for Pixuvri pixantrone to treat relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL) in patients who failed two or more lines of prior therapy. …

    Published on 1/30/2012
  • COMPANY NEWS: EC's non-decision keeps Glybera MAA alive

    Amsterdam Molecular Therapeutics Holding N.V. (Euronext:AMT) said the European Commission asked for more information from EMA's CHMP before it can make a final decision on an MAA for Glybera to treat lipoprotein lipase…

    Published on 1/30/2012
  • COMPANY NEWS: Partners launch campaign against 10 neglected diseases

    Thirteen biopharma companies partnered with several governments and international health organizations to eliminate or control 10 neglected tropical diseases by 2020. The partners agreed to sustain or expand existing …

    Published on 1/30/2012

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993

Log In


Forgot password  |  Forgot Login


If you are a subscriber, but have forgotten or have never received a password, please go here and ask us to send you a new one.

The Daily Extra

Concise and authoritative news for biotech and pharma, written each business day by BioCentury’s senior editors and analysts.


Find out how to get your biopharma daily news update.